Study shows elevated cardiac risk in boys 12-15

“For boys 12-15 without medical comorbidities receiving their second mRNA vaccination dose, the rate of CAE is 3.7-6.1 times higher than their 120-day COVID-19 hospitalization risk…”

A study published by MedRx looks at the rate of post-vaccination cardiac myocarditis in the 12-15 and 16-17-year-old age ranges in the context of their COVID-19 hospitalization risk.

The study’s conclusion found that adverse cardiac events were highest for boys ages 12-15 following dose two of the vaccine.

Using a total of 257 identified adverse reactions for both boys and girls, boys 12-15 with no comorbidities that had a second mRNA vaccination dose, “the rate of CAE is 3.7 to 6.1 times higher than their 120-day COVID-19 hospitalization risk as of August 21, 2021 (7-day hospitalizations 1.5/100k population) and 2.6-4.3-fold higher at times of high weekly hospitalization risk (7-day hospitalizations 2.1/100k), such as during January 2021.”

Boys ages 16-17 with no comorbidities had at a rate of adverse events “2.1 to 3.5 times higher than their 120-day COVID-19 hospitalization risk,” and “1.5 to 2.5 times higher at times of high weekly COVID-19 hospitalization.”

“For boys 12-17 without medical comorbidities, the likelihood of post-vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence,” the conclusion states. “Further research into the severity and long-term sequelae of post-vaccination CAE is warranted.”

Access the full study here.

Related Articles:

Pfizer vaccine could be authorized for kids ages 5 to 11 in October - NY Post

Will your K-12 student be required to get a COVID-19 shot? - North State Journal

Study: No lasting damage to lungs after COVID-19 in younger patients -